Display options
Cite
Di Stefano AFD, Radicioni MM, Vaccani A, et al. Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX. Antibiotics (Basel). 2021;10(2)doi: 10.3390/antibiotics10020167.
Di Stefano, A. F. D., Radicioni, M. M., Vaccani, A., Mazzetti, A., Longo, L. M., & Moro, L. (2021). Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX. Antibiotics (Basel, Switzerland), 10(2), . https://doi.org/10.3390/antibiotics10020167
Di Stefano, Andrea Francesco Daniele, et al. "Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX." Antibiotics (Basel, Switzerland) vol. 10,2 (2021). doi: https://doi.org/10.3390/antibiotics10020167
Di Stefano AFD, Radicioni MM, Vaccani A, Mazzetti A, Longo LM, Moro L. Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX. Antibiotics (Basel). 2021 Feb 06;10(2). doi: 10.3390/antibiotics10020167. PMID: 33562091; PMCID: PMC7915865.
Copy Download .nbib Format: NLM
Share it on

Antibiotics (Basel). 2021 Feb 06;10(2). doi: 10.3390/antibiotics10020167.

Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX.

Antibiotics (Basel, Switzerland)

Andrea Francesco Daniele Di Stefano, Milko Massimiliano Radicioni, Angelo Vaccani, Alessandro Mazzetti, Luigi Maria Longo, Luigi Moro

Affiliations

  1. CROSS Research S.A., Via F. A. Giorgioli, 14, CH-6864 Arzo, Switzerland.
  2. Cosmo Technologies Ltd., Riverside II, Sir John Rogerson's Quay, Dublin 2, Ireland.

PMID: 33562091 PMCID: PMC7915865 DOI: 10.3390/antibiotics10020167

Abstract

The primary objective of this single- and multiple-dose pharmacokinetic study was the investigation of rifamycin SV's pharmacokinetic profile in plasma and urine. All the 18 enrolled healthy men and post-menopausal women received modified release tablets containing 600 mg of the oral non-absorbable antibiotic, rifamycin SV, according to a multiple dose regimen: one tablet three times a day (daily intake: 1800 mg) for 14 consecutive days. Blood sampling and urine collection were performed up to 24 h post-dose after the first dose on Days 1 and 7. On average, on Day 1, C

Keywords: MMX; healthy subjects; non absorbable antibiotics; pharmacokinetics; rifamycin SV

References

  1. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1157-60 - PubMed
  2. Ther Adv Chronic Dis. 2013 Sep;4(5):223-31 - PubMed
  3. Experientia. 1960 Sep 15;16:412 - PubMed
  4. Am J Gastroenterol. 2008 Jun;103(6):1557-67 - PubMed
  5. JAMA. 2004 Aug 18;292(7):852-8 - PubMed
  6. Ann Intern Med. 1983 Jan;98(1):20-5 - PubMed
  7. Gut. 2013 Jan;62(1):159-76 - PubMed
  8. Antimicrob Agents Chemother. 2011 May;55(5):2122-8 - PubMed
  9. Arzneimittelforschung. 1965 Aug;15(8):Suppl:951-1002 - PubMed
  10. Br J Clin Pharmacol. 2006 Jan;61(1):31-8 - PubMed
  11. Clin Infect Dis. 1992 Nov;15 Suppl 1:S228-35 - PubMed
  12. Ann Intern Med. 2006 Oct 17;145(8):557-63 - PubMed
  13. Dig Dis Sci. 2008 Jun;53(6):1443-54 - PubMed
  14. J Breath Res. 2008 Dec;2(4):046002 - PubMed
  15. Ann Pharmacother. 2008 Mar;42(3):408-12 - PubMed
  16. Aliment Pharmacol Ther. 2003 Feb;17(3):395-402 - PubMed
  17. Am J Gastroenterol. 2000 Dec;95(12):3503-6 - PubMed

Publication Types